Australia markets open in 8 hours 49 minutes

GSK plc (GSK)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
43.69+0.94 (+2.20%)
At close: 04:00PM EDT
43.43 -0.26 (-0.60%)
After hours: 07:38PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close42.75
Open43.29
Bid43.43 x 1800
Ask43.60 x 3100
Day's range43.00 - 43.70
52-week range37.80 - 46.97
Volume3,928,254
Avg. volume5,656,983
Market cap111.061B
Beta (5Y monthly)0.29
PE ratio (TTM)17.69
EPS (TTM)2.47
Earnings date01 Feb 2017 - 06 Feb 2017
Forward dividend & yield1.99 (4.55%)
Ex-dividend date19 May 2022
1y target est49.15
  • Zacks

    Gilead (GILD) Announces Positive Data on Hepcludex for HDV

    Gilead (GILD) Hepcludex meets the primary endpoint in a phase III study for the treatment of chronic hepatitis delta virus (HDV) infection at 48 weeks.

  • Financial Times

    Sanofi-GSK Covid vaccine found effective against Omicron

    Sanofi and GlaxoSmithKline have reported promising results from trials of their Covid-19 vaccine, which has proved to be particularly effective against the Omicron strain of coronavirus. The vaccine targets the original and the Beta strains of coronavirus but was also tested against the more recent Omicron variant. When used as a first dose, it demonstrated a 64.7 per cent efficacy rate against symptomatic infection overall in adults, and was 72 per cent effective against infections caused by Omicron.

  • GlobeNewswire

    Viridian Therapeutics Appoints Carrie Melvin as Chief Operating Officer

    WALTHAM, Mass., June 23, 2022 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, today announced the appointment of Carrie Melvin as Chief Operating Officer, a newly created position at the company. “As we prepare for late-stage clinical development for our TED programs, we are excited to add Carrie to the Viridian team” said Jonathan Violin, Ph.D., Viridia